Travel-associated faecal colonization with esbl-producing enterobacteriaceae: Incidence and risk factors

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 9, 2013, Pages 2144-2153

  Östholm Balkhed, Åse ^a,b   Tärnberg, Maria ^a   Nilsson, Maud ^a   Nilsson, Lennart E ^a   Hanberger, Håkan ^a,b   Hällgren, Anita ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b County Council of Östergötland   (Sweden)

Author keywords

Antibiotic resistance; CTX M; Travel medicine

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE CTX M; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; CLOXACILLIN; COTRIMOXAZOLE; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LINEZOLID; MECILLINAM; MEROPENEM; NITROFURANTOIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TEMOCILLIN; TIGECYCLINE; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CONTROLLED STUDY; DISEASE CARRIER; ENTEROBACTER CLOACAE; EPSILOMETER TEST; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FECES ANALYSIS; FECES CULTURE; FECES MICROFLORA; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC CODE; GENOTYPE; HUMAN; INCIDENCE; INDIAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NORTH AFRICA; OBSERVATIONAL STUDY; PHENOTYPE; PROSPECTIVE STUDY; PROTEUS VULGARIS; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SCANDINAVIA; SWEDEN; TRAVEL;

ANTIBIOTIC RESISTANCE; CTX-M; TRAVEL MEDICINE;

ADOLESCENT; ADULT; AGED; BETA-LACTAMASES; COHORT STUDIES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FECES; FEMALE; GENOTYPE; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SWEDEN; TRAVEL; YOUNG ADULT;

EID: 84882656454     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt167     Document Type: Article

References (40)

1. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64 Suppl 1: 3-10.
2. Doumith M, Dhanji H, Ellington MJ et al. Characterization of plasmids encoding extended-spectrum b-lactamases and their addiction systems circulating among Escherichia coli clinical isolates in the UK. J Antimicrob Chemother 2012; 67: 878-85.
3. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008; 13: pii1/419044.
4. Valverde A, Grill F, Coque TM et al. High rate of intestinal colonization with extended-spectrum-b-lactamase-producing organisms in household contacts of infected communitypatients. J Clin Microbiol 2008;46: 2796-9.
5. Rodriguez-Bano J, Lopez-Cerero L, Navarro MD et al. Faecal carriage of extended-spectrum b-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 2008; 62: 1142-9.
6. Lo WU, Ho PL, Chow KH et al. Fecal carriage of CTXM type extended-spectrum b-lactamase-producing organisms by children and their household contacts. J Infect 2010; 60: 286-92.
7. Laupland KB, Church DL, Vidakovich J et al. Community-onset extended-spectrum b-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 2008; 57: 441-8.
8. Tham J, Odenholt I, Walder M et al. Extended-spectrum b-lactamase-producing Escherichia coli in patients with travellers' diarrhoea. Scand J Infect Dis 2010; 42: 275-80.
9. Peirano G, Laupland KB, Gregson DB et al. Colonization of returning travelers with CTX-M-producing Escherichia coli. J Travel Med 2011; 18: 299-303.
10. Tängden T, Cars O, Melhus A et al. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extendedspectrum b-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010; 54: 3564-8.
11. Kennedy K, Collignon P. Colonisation with Escherichia coli resistant to 'critically important' antibiotics: a high risk for international travellers. Eur J Clin Microbiol Infect Dis 2010; 29: 1501-6.
12. Giske CG, Sundsfjord AS, Kahlmeter G et al. Redefining extended-spectrum b-lactamases: balancing science and clinical need. J Antimicrob Chemother 2009; 63: 1-4.
13. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
14. EUCAST (2013). Breakpoint Tables for Interpretation of MICs and Zone Diameters. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_Breakpoint_table_v_3.0.xls (21 January 2013, date last accessed).
15. BSAC (2011). BSAC Methods for Antimicrobial Susceptibility Testing. http://bsac.org.uk/wp-content/uploads/2012/02/Version-10.2-2011-final- May-20111.pdf (21 January 2013, date last accessed).
16. Monstein HJ, Tarnberg M, Nilsson LE. Molecular identification of CTX-M and blaOXY/K1 b-lactamase genes in Enterobacteriaceae by sequencing of universal M13-sequence tagged PCR-amplicons. BMC Infect Dis 2009; 9: 7.
17. Tarnberg M, Nilsson LE, Monstein HJ. Molecular identification of (bla)SHV, (bla)LEN and (bla)OKP b-lactamase genes in Klebsiella pneumoniae by bi-directional sequencing of universal SP6-and T7-sequence-tagged (bla)SHV-PCR amplicons. Mol Cell Probes 2009; 23: 195-200.
18. Ostholm-Balkhed A, Tarnberg M, Nilsson M et al. Prevalence of extended-spectrum b-lactamase-producing Enterobacteriaceae and trends in antibiotic consumption in a county of Sweden. Scand J Infect Dis 2010; 42: 831-8.
19. Péréz-Péréz FJ, Hanson ND. Detection of plasmid-mediated AmpC b-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002; 40: 2153-62.
20. Stromdahl H, Tham J, Melander E et al. Prevalence of faecal ESBL carriage in the community and in a hospital setting in a county of Southern Sweden. Eur J Clin Microbiol Infect Dis; 30: 1159-62.
21. Woerther PL, Angebault C, LescatMet al. Emergenceand dissemination of extended-spectrum b-lactamase-producing Escherichia coli in the community: lessons from the study of a remote and controlled population. J Infect Dis 2010; 202: 515-23.
22. Luvsansharav UO, Hirai I, Niki M et al. Prevalence of fecal carriage of extended-spectrum b-lactamase-producing Enterobacteriaceae among healthy adult people in Japan. J Infect Chemother 2011; 17: 722-5.
23. Herindrainy P, Randrianirina F, Ratovoson R et al. Rectal carriage of extended-spectrum b-lactamase-producing Gram-negative bacilli in community settings in Madagascar. PLoS One 2011; 6: e22738.
24. Tian SF, Chen BY, Chu YZ et al. Prevalence of rectal carriage of extended-spectrum b-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol 2008; 54: 781-5.
25. Kader AA, Kumar A, Kamath KA. Fecal carriage of extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol 2007; 28: 1114-6.
26. Abdul Rahman EM, El-Sherif RH. High rates of intestinal colonization with extended-spectrum lactamase-producing Enterobacteriaceae among healthy individuals. J Investig Med 2011; 59: 1284-6.
27. Sasaki T, Hirai I, Niki M et al. High prevalence of CTX-M b-lactamase-producing Enterobacteriaceae in stool specimens obtained from healthy individuals in Thailand. J Antimicrob Chemother 2010; 65: 666-8.
28. Calbo E, Freixas N, Xercavins Met al. Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae: epidemiology and control. Clin Infect Dis 2011; 52: 743-9.
29. Frank C, Werber D, Cramer JP et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365: 1771-80.
30. Hao R, Qiu S, Wang Y et al. Quinolone-resistant Escherichia coli O127a:K63 serotype with an extended-spectrum-b-lactamase phenotype from a food poisoning outbreak in China. J Clin Microbiol 2012; 50: 2450-1.
31. Raju B, Ballal M. Multidrug resistant enteroaggregative Escherichia coli diarrhoea in rural southern Indian population. Scand J Infect Dis 2009; 41: 105-8.
32. Hawkey PM. Prevalence and clonality of extended-spectrum b-lactamases in Asia. Clin Microbiol Infect 2008; 14 Suppl 1: 159-65.
33. Kuroda H, Yano H, Hirakata Y et al. Molecular characteristics of extended-spectrum b-lactamase-producing Escherichia coli in Japan: emergence of CTX-M-15-producing E. coli ST131. Diagn Microbiol Infect Dis 2012; 74: 201-3.
34. An S, Chen J, Wang Z et al. Predominant characteristics of CTX-M-producing Klebsiella pneumoniae isolates from patients with lower respiratory tract infection in multiple medical centers in China. FEMS Microbiol Lett 2012; 332: 137-45.
35. Ma J, Liu JH, Lv L et al. Characterization of extended-spectrum b-lactamase genes found among Escherichia coli isolates from duck and environmental samples obtained on a duck farm. Appl Environ Microbiol 2012; 78: 3668-73.
36. Snow LC, Warner RG, Cheney T et al. Risk factors associated with extended spectrum b-lactamase Escherichia coli (CTX-M) on dairyfarms in North West England and North Wales. Prev Vet Med 2012; 106: 225-34.
37. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum b-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 913-20.
38. Jeon MH, Choi SH, Kwak YG et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. Diagn Microbiol Infect Dis 2008; 62: 402-6.
39. Martinez JA, Cobos-Trigueros N, Soriano A et al. Influence of empiric therapy with a b-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to Gram-negative microorganisms. Antimicrob Agents Chemother 2010; 54: 3590-6.
40. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: 103-20.